Short answer
Bioventus Inc. (BVS) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 26, 2026. Quarterly revenue was $142M (up 2.7% year over year) with net income of $6M.
Q3 2026 key financials · XBRL
- Revenue
- $142M
- +2.7% YoY · −7.0% QoQ
- Net income
- $6M
- +89.8% YoY · −82.1% QoQ
- Operating margin
- 6.8%
- Gross margin
- 68.2%
- EPS (diluted)
- $0.08
- +60.0% YoY · −83.3% QoQ
Source: XBRL data from the Bioventus Inc. (BVS) Q3 2026 10-Q on SEC EDGAR. USD.
Bioventus Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $142.4M, up $3.8M or 2.7% YoY
- Operating margin 6.8% vs 8.1% YoY, net income $6.9M vs $4.0M
- Best segment: International Surgical Solutions, sales $6.8M, up 31.0% YoY
- Worst segment: International Restorative Therapies, sales $2.6M, down 10.5% YoY
- Operating cash flow $49.5M, up $12.8M; debt repayments $64.5M and cash $30.7M vs $51.2M at year-end
Risk Factors
- No material risk-factor changes from the 2025 10-K and June 27, 2026 Form 10-Q
- Carried-forward business risks could materially affect financial condition or future results
- Unknown or currently immaterial risks may adversely affect business performance
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bioventus Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.